Clinical Report: Efficacy of Osimertinib in HER2-Positive DCIS
Overview
This case report highlights the significant response of a 74-year-old woman with HER2-positive ductal carcinoma in situ (DCIS) to osimertinib, an EGFR inhibitor used for non-small cell lung cancer (NSCLC). The findings suggest that osimertinib may have therapeutic effects on HER2-positive DCIS, warranting further investigation.
Background
Ductal carcinoma in situ (DCIS) is a prevalent non-invasive breast cancer that poses a risk of progression to invasive ductal carcinoma (IDC). HER2-positive DCIS is associated with higher histological grades and increased local recurrence risk. Current treatment protocols for HER2-positive DCIS do not include targeted therapies, highlighting the need for innovative treatment options.
Data Highlights
Measurement
Before Treatment
After Treatment
Tumor Size (mm)
28 x 11 x 29
8 x 3
Ki-67 Index
20-30%
1%
Key Findings
The patient exhibited a marked reduction in tumor size from 28 x 11 x 29 mm to 8 x 3 mm after osimertinib treatment.
Ki-67 index decreased significantly from 20-30% to 1%, indicating reduced cell proliferation.
Osimertinib demonstrated in vitro inhibition of HER2 phosphorylation and cell proliferation in HER2-positive cells.
HER2-positive DCIS is typically treated with surgical resection and radiotherapy, with limited evidence for systemic anti-HER2 therapies.
This case suggests a potential role for osimertinib in treating HER2-positive breast cancer, including DCIS.
Clinical Implications
The findings from this case report suggest that osimertinib may offer a novel therapeutic avenue for patients with HER2-positive DCIS, particularly those with concurrent EGFR mutations. Further clinical trials are necessary to validate these results and explore the potential of osimertinib as a standard treatment option.
Conclusion
This case highlights the potential efficacy of osimertinib in HER2-positive DCIS, suggesting a need for further research to establish its role in breast cancer treatment protocols. The significant tumor response observed warrants exploration in larger clinical studies.
